Pil Soo Sung1,2, Keungmo Yang1, Si Hyun Bae3,4, Jung Suk Oh5, Ho Jong Chun5, Hee Chul Nam1, Jeong Won Jang1,2, Jong Young Choi1,2, Seung Kew Yoon1,2. 1. Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. 2. The Catholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 3. The Catholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea baesh@catholic.ac.kr. 4. Department of Internal Medicine, College of Medicine, St. Paul's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. 5. Department of Radiology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract
BACKGROUND/AIM: This study aimed to identify the survival benefit of intrahepatic tumour control by hepatic arterial infusion chemotherapy (HAIC) in hepatocellular carcinoma (HCC) patients with portal vein tumour thrombus (PVTT) or extrahepatic metastasis. PATIENTS AND METHODS: Between 2010 and 2017, a total of 187 consecutive patients with advanced HCC were treated with HAIC. The survival outcomes and response rates to HAIC were analysed. RESULTS: The intrahepatic objective response (OR) rate of all enrolled patients was 18.7%. The survival outcome of patients with OR was significantly better from those without OR, irrespective of initial distant metastasis. Achievement of intrahepatic OR by HAIC and favourable liver function at the time of best response evaluation were two independent factors associated with better OS. CONCLUSION: HAIC-induced intrahepatic tumour reduction significantly prolonged patient survival, irrespective of PVTT or initial distant metastasis. Copyright
BACKGROUND/AIM: This study aimed to identify the survival benefit of intrahepatic tumour control by hepatic arterial infusion chemotherapy (HAIC) in hepatocellular carcinoma (HCC) patients with portal vein tumour thrombus (PVTT) or extrahepatic metastasis. PATIENTS AND METHODS: Between 2010 and 2017, a total of 187 consecutive patients with advanced HCC were treated with HAIC. The survival outcomes and response rates to HAIC were analysed. RESULTS: The intrahepatic objective response (OR) rate of all enrolled patients was 18.7%. The survival outcome of patients with OR was significantly better from those without OR, irrespective of initial distant metastasis. Achievement of intrahepatic OR by HAIC and favourable liver function at the time of best response evaluation were two independent factors associated with better OS. CONCLUSION: HAIC-induced intrahepatic tumour reduction significantly prolonged patient survival, irrespective of PVTT or initial distant metastasis. Copyright
Authors: Pil Soo Sung; Moon Hyung Choi; Hyun Yang; Soon Kyu Lee; Ho Jong Chun; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon; Joon-Il Choi; Young Joon Lee; Si Hyun Bae Journal: Front Oncol Date: 2020-11-19 Impact factor: 6.244